Role of endocardial septal ablation in the treatment of hypertrophic obstructive cardiomyopathy
1Department of Cardiology, Kocaeli Derince Education and Research Hospital; Kocaeli-Turkey
2Department of Cardiology, Bayrampaşa Kolan Hospital; İstanbul-Turkey
Anatol J Cardiol 2016; 9(16): 707-712 PubMed ID: 27609434 PMCID: 5331357 DOI: 10.14744/AnatolJCardiol.2016.7100
Full Text PDF

Abstract

Septal reduction therapy is accepted as a first therapeutic option for symptomatic drug-resistant hypertrophic obstructive cardiomyopathy (HOCM). Although, surgical septal myectomy is the gold standard method, alcohol septal ablation is a well-studied alternative approach in the patients with suitable anatomy. Endocardial septal ablation (ESA) therapy was relatively new defined modality and outcomes of the procedure were not clearly elucidated yet. We aimed to review the clinical aspects of ESA procedure and provide some historical background. (Anatol J Cardiol 2016; 16: 707-12)